ACN 097 011 188 Pty Ltd v Alphapharm Pty Ltd

Link copied
Case Copied 48 min read

DISTRICT COURT OF QUEENSLAND

CITATION: 

ACN 097 011 188 Pty Ltd & Ors v Alphapharm Pty Ltd [2024] QDC 74

PARTIES: 

ACN 097 011 188 PTY LTD

(First Plaintiff)

DARRYL EDWARD KIRK AND BRUNO ROBERT ANTHONY SECATORE IN THEIR CAPACITY AS LIQUIDATORS OF ACN 097 011 188 PTY LTD (IN LIQUIDATION) (FORMERLY MEDICATION PACKAGING SYSTEMS (AUSTRALIA) PTY LTD)

(Second Plaintiff)

v

ALPHAPHARM PTY LTD ACN 002 359 739
(First Defendant)

FILE NO:

638/23

DIVISION:

Civil

PROCEEDING:

Claim

ORIGINATING COURT: 

District Court

DELIVERED ON:

26 April 2024 (ex tempore)

DELIVERED AT:

Brisbane

HEARING DATE: 

22 and 24 April 2024

JUDGE:

Porter KC DCJ

ORDER:

1.    The first defendant pay to the second plaintiff:

(a)      The $620,892.24; and

(b)     Interest from 12 March 2021 in the sum of $112,165.13.

2.   The first defendant pay the plaintiffs’ costs of the proceeding to the extent that those costs were incurred in this proceeding as against the first defendant:

(a)     On the standard basis up to and including 16 September 2021; and

(b)     On the indemnity basis from 17 September 2021.

CATCHWORDS:

CORPORATIONS – Winding up – Winding up in insolvency – Effect of winding up on other transactions – Preferences and voidable transactions – Unfair preferences – where the second plaintiffs are liquidators of the Company – where the defendant was a supplier to the Company – where the Company owed the first defendant $820,000 and paid the defendant $620,892.24 on 29 September 2017 – where plaintiff sues to recover that payment as an unfair preference – where the payment was made immediately preceding settlement of a sale of the Company’s assets on 3 October 2017 – where the defendant defends on the sole basis that the Company was not insolvent when the Payment was made – whether the Company was insolvent when the Payment was made where, at settlement of a sale of its operating assets on 3 October 2017, the Company would cease to have any assets to carry on previous business – whether the Company was able to meet its debts as and when they fell due, including debts payable in the near future, as at 29 September 2017

CASES:

Anchorage Capital Master Offshore Ltd v Sparkes [2023] NSWCA 88

Bank of Australasia v Hall (1907) 4 CLR 1514

COUNSEL:

L Copley for the Plaintiffs

M Jones KC for the Defendant

SOLICITORS:

Stratos Legal for the Plaintiffs

Mills Oakley Lawyers for the Defendant

Contents

Summary
The facts
The Liquidators’ case on insolvency
Alphapharm’s case
Relevant principles
The first argument: the Standstill Deed

The company’s position post settlement

The second argument: cashflow position

Conclusion

Summary

  1. The plaintiffs are liquidators of ACN 097 011 188 Pty Ltd, formerly MPS Pty Ltd (the Company). They sue the defendant (Alphapharm) to recover $620,892.24 paid on 29 September 2017 (the Payment) as an unfair preference. Alphapharm defends on one basis only: that the Company was not insolvent when the Payment was made. For the reasons that follow, I find that…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read ACN 097 011 188 Pty Ltd v Alphapharm Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] QDC 74
Decision Date

CaseChat Overview and Summary

ACN 097 011 188 Pty Ltd (the Company), through its liquidators, the second plaintiffs, brought an action against Alphapharm Pty Ltd (the first defendant) to recover a payment made by the Company to the first defendant as an unfair preference under the Corporations Act 2001 (Cth). The Company, which was insolvent at the time of the payment, had made a payment of $620,892.24 to the first defendant on 29 September 2017. The first defendant contended that the Company was not insolvent at the time of the payment. The court was required to determine whether the Company was insolvent at the time of the payment, and if so, whether the payment constituted an unfair preference.

The court found that the Company was indeed insolvent at the time of the payment. The Company was unable to meet its debts as and when they fell due, as evidenced by the fact that it would cease to have any assets to carry on its previous business upon settlement of a sale of its operating assets on 3 October 2017. The payment to the first defendant was made immediately preceding this settlement, which constituted an unfair preference. The court held that the first defendant was required to repay the amount of the payment, along with interest from 12 March 2021.

The court ordered that the first defendant pay the Company $620,892.24, plus interest from 12 March 2021 in the sum of $112,165.13. The court also ordered the first defendant to pay the plaintiffs' costs of the proceeding to the extent that those costs were incurred in the proceeding as against the first defendant, on the standard basis up to and including 16 September 2021, and on the indemnity basis from 17 September 2021.

Orders

Orders of the court

1. The first defendant pay to the second plaintiff:

(a) The $620,892.24; and

(b) Interest from 12 March 2021 in the sum of $112,165.13.

2. The first defendant pay the plaintiffs’ costs of the proceeding to the extent that those costs were incurred in this proceeding as against the first defendant:

(a) On the standard basis up to and including 16 September 2021; and

(b) On the indemnity basis from 17 September 2021.

Background

Background to the litigation

The Standstill Deed relevantly provided as follows:(a)By Background:BackgroundA NAB and the Borrowing Entities have entered into the NAB Facility Agreements. B The Nab Securities secure the Borrowing Entities’ obligations under the NAB Facility Agreements. C Sigma and the Principals have entered into the Supply Agreements. D The Sigma Securities secure the Principals’ obligations under the Supply Agreements. E The parties to this deed have agreed to manage the commercial relationship as between them on the terms set out in this deed. (b)By defined terms:Defined terms[…]Borrowing Entities means the MPS Borrowing Entities and the Pharmancy Borrowing Entities.[…]MPS Borrowing Entities means each of the following in their capacity as borrowers pursuant to the MPS Facility Agreements:(a) MPS; and (b) Dose.[…]Pharmacy Borrowing Entities means each of the following in their capacity as borrowers pursuant to the Pharmacy Facility Agreements:(a) Castrisos; (b) Maroochydore Discount Drug Store; (c) PharmaSave Acacia Ridge Pharmacy; (d) Souzani Adasan;(e) Think Pharmacy Aspley; (f) Think Pharmacy Chermside;(g) Think Pharmacy Kippa Ring; (h) TPAS. […]Principals means (subject to clause 3.1 Allen, Castrisos and Souzani, whether in their individual capacity or in partnership with one or more of them, or others.[…]Standstill End Date means 31 March 2017 or such later date to which the Lenders agree in writing in their absolute discretion. Standstill Period means the Effective Date to the Standstill End Date, unless the Standstill Period is terminated at an earlier date in accordance with Clause 9 of this deed.[…]Think Pharmacy Group means the Principals (in their own capacities and trading as the Think Pharmacies), Dose, Dose Holdings, MPS, MPS No. 2, MPS No. 3, Souzani Pty Ltd and TPAS. (c)By clause 4.1, sub-clauses (d), (e) and (h):4.1 BorrowersEach of the Borrowing Entities acknowledge, warrant and agree that:[…](d)the Borrowing Entities are in default of the NAB Facility Agreements and the NAB Securities to which they are parties;(e)NAB expressly reserves its rights in respect of the previous and subsisting defaults under the NAB Facility Agreements and the NAB Securities, which defaults are not waived in any manner by the execution or performance of this deed;[…](h)this deed in no way commits NAB to provide any additional funding and no reliance may be placed by the Borrowing Entities on any additional funding being made available by NAB at any time. (d)By clause 4.3:4.3 Cross-collateralisation Subject to clause 4.4, each of the Borrowing Entities and each of the Guarantors jointly and severally covenant and agree with NAB that each of the NAB Securities to which they are parties secures the Amount Owing and any other liabilities, obligations and covenants of each of the Borrowing Entities under: (a) all of the NAB Facilities; (b) all other facilities that NAB may provide from time to time to any Borrowing Entity or Guarantor, either alone or with others; and(c) this deed.(e)By clause 4.5:4.5 Cross-collateralisation Each of the Borrowing Entities and each of the Guarantors jointly and severally acknowledge and agree that: (a) an event of default or breach of the terms and conditions of any NAB Facility Agreement or any NAB Security will constitute an event of default under all of the NAB Facility Agreements and all of the NAB Securities; (b) an event of default or breach of the terms and conditions of any Supply Agreement will constitute an event of default under all of the NAB Facility Agreements and all of the NAB Securities; (c) subject to clause 9.1 of this deed, upon default pursuant to any of the NAB Facility Agreements or the NAB Securities, notwithstanding any other provision of the NAB Facility Agreements or the NAB Securities: (i) all moneys owing pursuant to the NAB Facility Agreements, or under the NAB Securities, shall be immediately payable to NAB; and(ii) NAB may recover all such monies by exercising its rights under all or any one or more of the NAB Securities; and (iii) NAB will be entitled to enforce any of the NAB Securities without reference to the others and without first having resort to its rights under any of the other NAB Securities.(f)By clause 5.1, sub-clause (a):5.1 Sigma Debt owing(a) The Principals (other than Souzani and Souzani Pty Ltd) acknowledge and agree that: (i) they are indebted to Sigma for the whole of the Sigma Debt, free of any set off, cross claim or deduction; and (ii) as at 17 February 2017, the Sigma Debt totals $14,167,259.69, with interest and costs continuing to accrue.(g)By clause 6.3:6.3 Restructure Plans(a) The Principals have submitted an asset realisation plan for the Retail Pharmacies (Retail Pharmacies Sale). (b) By no later than 28 February 2017, the Principals must submit a draft Restructure Plan to NAB, setting out a detailed proposal for the sale and/or restructure of the assets of the MPS Businesses, Dose and Dose Holdings, including timelines and proposed marketing strategies (MPS ARP). (c) The Think Pharmacy Group must not enter into any contract or option for the sale of any of the assets of the Think Pharmacy Group without the prior written consent of NAB. (d) The Think Pharmacy Group will: (i) provide any information reasonably requested by NAB as to the status of the Restructure Plans, or answer any questions NAB may have, from time to time in relation to the Restructure Plans; and (ii) provide any information reasonably requested by Sigma as to the status of the Retail Pharmacies Sale, or answer any questions Sigma may have in relation to the status of the Retail Pharmacies Sale, from time to time. (e) The Think Pharmacy Group will send to NAB any offers it receives in respect of any one or more of its businesses including any of the Retail Pharmacies. (f) The Think Pharmacy Group must take all reasonable steps to ensure that the value of their assets is preserved and otherwise maximised throughout the Standstill Period. (g) The Think Pharmacy Group must ensure that: (i) the business and financial records of the MPS Businesses, Dose and Dose Holdings are complete and accurate in all material respects and available for inspection at reasonable times by NAB, its advisors and any purchaser/s; and (ii) the business and financial records of the Think Pharmacies are complete and accurate and available for inspection at reasonable times by the Lenders, their advisors and any purchaser/s. (h) The Principals must not reject any offer made to them in relation to any one or more of the Retail Pharmacies without first consulting with NAB.(h)By clause 7, sub-clause (a):7. Restructure Plans(a) Castrisos, Allen, Dose, Dose Holdings, MPS, MPS No 2 and MPS No 3 undertake to execute a general security agreement over all of their assets and undertaking in favour of Sigma (New Sigma Security 1), to secure the obligations of the Principals pursuant to the Supply Agreements.(i)By clauses 8.1 and 8.2:8.1 NAB Standstill (a) Subject always to clause 9 below, NAB agrees: (i) not to make any demand for payment or exercise any of its Enforcement Rights during the Standstill Period; and (ii) not to charge interest during the Standstill Period other than at the Uniform Rate. (b) The parties agree that no further amounts will be drawn or made available pursuant to the existing NAB Facilities, or any new facility, unless required for working capital purposes. (c) NAB will notify Sigma of any further amounts drawn or made available pursuant to the existing NAB Facilities, or any new facility, where the amount drawn or made available exceeds $50,000. (d) Any amounts drawn or advanced by NAB pursuant to subclause (b) after the date of this deed above will be subject to the priority regime set out in the Deed of Priority. 8.2 Sigma Standstill (a) Subject always to clauses 8.2(c) and 9 below and the Principals continuing compliance with the terms of this deed, Sigma agrees that during the Standstill Period it will not make any demand for payment or retake possession of any pharmacy stock from any member of the Think Pharmacy Group, or otherwise exercise any of its Enforcement Rights (Sigma Standstill). (b) Nothing in this deed entitles a Think Pharmacy to a settlement credit or discount (however described) unless it pays an invoice within terms.(c) The Sigma Standstill does not apply in relation to the Principals or any one or more of them trading either as sole trader or in partnership as any pharmacy other than the Think Pharmacies.(j)By clause 9:9. Termination of Standstill Period(a) Unless a Trigger Event occurs, the Standstill Period terminates on the Standstill End Date. (b) A Trigger Event occurs if any of the following events occur:… (c) If the Lenders (or any one of them), acting in their sole discretion, determine that a Trigger Event has occurred, then: (i) they must give notice to the other parties' to this deed, in accordance with clause 16 below; and (ii) upon the expiry of 24 hours from the time of giving the notice, a Trigger Event will be deemed to have occurred. (d) The Think Pharmacy Group agrees that if the Standstill Period ends (either due to a Trigger Event or upon expiration of the Standstill Period): (i) the Lenders may immediately and without notice to the Think Pharmacy Group exercise any of their Enforcement Rights; (ii) the Think Pharmacy Group will co-operate with the exercise of such Enforcement Rights; (iii) the Amount Owing will become immediately due and payable and NAB may rely on this deed as conclusive evidence of the Think Pharmacy Group's consent to judgment being entered against them for the balance of the Amount Owing then outstanding; and (iv) the Sigma Debt will become immediately due and payable and Sigma may rely on this deed as conclusive evidence of the Think Pharmacy Group's consent to judgment being entered against them for the balance of the Sigma Debt then outstanding.